OncoImmunology · 2024 · 19 citations · 34 references
MedicineImmunologyOncologyImmunotherapyMolecular OncologyTumor MicroenvironmentCancer MetabolismImmune Cell MetabolismImmune Checkpoint RegulationMetabolic ReprogrammingMetabolic Reprogramming In CancerRedox MetabolismCheckpoint Resistance MechanismsImmune Cell Metabolic ReprogrammingLung AdenocarcinomaMetabolic Alterations In CancerResistance To Checkpoint InhibitorsResistance To Immune Checkpoint InhibitionTissue-resident Memory T CellsTumor Microenvironment Effects
Metabolism reprogramming within the tumor microenvironment (TME) can have a profound impact on immune cells. Identifying the association between metabolic phenotypes and immune cells in lung adenocarcinoma (LUAD) may reveal mechanisms of resistance to immune checkpoint inhibitors (ICIs). Metabolic phenotypes were classified by expression of metabolic genes. Somatic mutations and transcriptomic features were compared across the different metabolic phenotypes. The metabolic phenotype of LUAD is predominantly determined by reductase-oxidative activity and is divided into two categories: redoxhigh LUAD and redoxlow LUAD. Genetically, redoxhigh LUAD is mainly driven by mutations in KEAP1, STK11, NRF2, or SMARCA4. These mutations are more prevalent in redoxhigh LUAD (72.5%) compared to redoxlow LUAD (17.4%), whereas EGFR mutations are more common in redoxlow LUAD (19.0% vs. 0.7%). Single-cell RNA profiling of pre-treatment and post-treatment samples from patients receiving neoadjuvant chemoimmunotherapy revealed that tissue-resident memory CD8+ T cells are responders to ICIs. However, these cells are significantly reduced in redoxhigh LUAD. The redoxhigh phenotype is primarily attributed to tumor cells and is positively associated with mTORC1 signaling. LUAD with the redoxhigh phenotype demonstrates a lower response rate (39.1% vs. 70.8%, p = 0.001), shorter progression-free survival (3.3 vs. 14.6 months, p = 0.004), and overall survival (12.1 vs. 31.2 months, p = 0.022) when treated with ICIs. The redoxhigh phenotype in LUAD is predominantly driven by mutations in KEAP1, STK11, NRF2, and SMARCA4. This phenotype diminishes the number of tissue-resident memory CD8+ T cells and attenuates the efficacy of ICIs.
34
Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle et al. · CA A Cancer Journal for Clinicians · 2023 · 16.7K citations · Full text
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016 · 4.8K citations · Full text
Medicine, Oncology, Pharmacology +13
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz, Ulrike Litzenburger, Felix Sahm et al. · Nature · 2011 · 1.9K citations · Full text
Medicine, Cancer Biology, Oncology +13
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Francisco J. Quintana, Alexandre S. Basso, Antonio Iglesias et al. · Nature · 2008 · 1.8K citations